Composition containing copper-blue peptide, preparation method of composition and application of composition in cosmetics

Abstract

The invention provides a blue copper peptide-containing composition as well as a preparation method and application thereof in cosmetics, belongs to the technical field of cosmetic processing, and solves the technical problems of low preparation and production efficiency, poor skin care effect and the like of an existing cosmetic composition. The composition consists of the following components: an A-phase raw material, a B-phase raw material, a C-phase raw material and a D-phase raw material, wherein the A-phase raw material consists of the following units: a unit 1, a unit 2, a unit 3, a unit 4, a unit 5, a unit 8, a unit 11, a unit 12 and a unit 19. The preparation method comprises the following preparation steps: warehousing the packing material; warehousing the raw materials; primarily preparing raw materials; adding all A-phase raw materials; b, adding and mixing the phase C; adding and mixing the phase D; a material body finished product; testing a material body finished product; filling and packaging; and packaging and testing finished products. A perfect quality control system from a source to a finished product is established, the preparation efficiency is high, and the composition is good in skin care effect, stable, good in safety and high in consistency.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of cosmetic processing, and relates to a composition containing blue copper peptide, in particular to a preparation method of the composition containing blue copper peptide and application of the composition in cosmetics. BACKGROUND

[0002] As a core active ingredient, the biological activity of blue copper peptide is highly dependent on the chelation state of copper ions. It is easily degraded, inactivated or color changed (blue-green) under high temperature, light, extreme pH value, the presence of certain metal ions or oxidants, resulting in a significant decrease or even complete loss of efficacy.

[0003] However, the traditional cosmetic emulsification process usually mixes and homogenizes the oil and water phases at a relatively high temperature (70-85℃), which is devastating to blue copper peptide. Therefore, it is urgent to develop a special process that can avoid high temperature, prevent incompatible ingredients from premature contact, and maximize the protection of the structural integrity of blue copper peptide.

[0004] The composition formula usually contains various oils, emulsifiers, thickeners, humectants, other active ingredients, preservatives, and possibly powders or particles. The physicochemical properties (polarity, solubility, ionicity, sensitivity to shear / temperature) of these ingredients differ greatly. The order, temperature, mixing intensity (stirring / homogenization) and timing of adding each component need to be carefully controlled to ensure: sufficient uniform dispersion / dissolution, stable emulsion system, and avoid adverse interactions between ingredients.

[0005] At the same time, it is also necessary to ensure product safety, effectiveness and quality stability. A clear non-conforming product handling process needs to be established, and all steps need to be traceable.

[0006] Therefore, we propose a composition containing blue copper peptide and its preparation method and application in cosmetics. SUMMARY

[0007] The purpose of the present application is to solve the above-mentioned problems existing in the prior art, and to provide a composition containing blue copper peptide and its preparation method and application in cosmetics. The technical problem to be solved by the present application is: how to realize stable and efficient production of cosmetic compositions containing blue copper peptide, while ensuring that the cosmetic compositions containing blue copper peptide have the functions of moisturizing, multiple soothing, relieving dry and uncomfortable skin, and safety.

[0008] The purpose of the present application can be achieved by the following technical solutions:

[0009] A phase raw material (by weight parts): 91.00, B phase raw material (by weight parts): 50.17, C phase raw material (by weight parts): 2.30 and D phase raw material (by weight parts): 22.25;

[0010] wherein the A phase raw material consists of the following units by weight parts: Unit 1 (by weight parts): 50, Unit 2 (by weight parts): 12.5, Unit 3 (by weight parts): 13, Unit 4 (by weight parts): 7, Unit 5 (by weight parts): 5, Unit 8 (by weight parts): 2.8, Unit 11 (by weight parts): 0.5, Unit 12 (by weight parts): 0.2 and Unit 19 (by weight parts): 0.001;

[0011] The B phase raw material consists of the following units: Unit 1 (by weight parts): 50 and Unit 13 (by weight parts): 0.17;

[0012] The C phase raw material consists of the following units: Unit 9 (by weight parts): 2.3 and Unit 20 (by weight parts): 0.001;

[0013] The D phase raw material consists of the following units: Unit 2 (by weight parts): 12.5, Unit 6 (by weight parts): 4.7, Unit 7 (by weight parts): 3, Unit 10 (by weight parts): 1.7, Unit 14 (by weight parts): 0.13, Unit 15 (by weight parts): 0.1, Unit 16 (by weight parts): 0.07, Unit 17 (by weight parts): 0.05 and Unit 18 (by weight parts): 0.001.

[0014] Unit 1 is water;

[0015] Unit 2 is butylene glycol;

[0016] Unit 3 is made by mixing the following components in the following mass percentages: 85% of Saccharomyces Lycium Ferment Filtrate, 10% of 1,2-hexanediol and 5% of p-hydroxyacetophenone;

[0017] Unit 4 is glycerin;

[0018] Unit 5 is glyceryl ether-26;

[0019] Unit 6 is made by mixing the following components in the following mass percentages: 40% of 1,3-propanediol, 55.75% of water, 0.25% of octanoyl hydroxamic acid, 2% of ethylhexylglycerin and 2% of 1,2-hexanediol;

[0020] Unit 7 is 1,2-hexanediol;

[0021] Unit 8 is trehalose;

[0022] Unit 9 is a mixture of the following components in weight percentages: water 70.3%, caprylic / capric triglycerides 5%, glycerin 8%, hydrogenated lecithin 5%, inulin lauryl carbamate 1.2%, shea butter 6%, macadamia seed oil 3%, 1,2-hexanediol 1%, and sodium palmitoyl sarcosinate 0.5%;

[0023] Unit 10 is made by mixing the following components in the following mass percentages: xylitol glucoside 3%, dehydrated xylitol 1%, water 94%, and xylitol 2%;

[0024] Unit 11 is an acrylic (ester) / C10-30 alkanol acrylate crosslinked polymer;

[0025] Unit 12 is xanthan gum;

[0026] Unit 13 is arginine;

[0027] Unit 14 is made by mixing the following components in the indicated weight percentages: 58% water, 5% 1,2-pentanediol, 10% acetylated sodium hyaluronate, 2% sodium hyaluronate, 20% sodium hyaluronate crosspolymer, 2.5% hydrolyzed sodium hyaluronate, and 2.5% ethylhexylglycerin.

[0028] Unit 15 is made from a mixture of the following components by weight percentage: 5% Spirulina macrophylla extract, 89% water, and 6% 1,2-pentanediol;

[0029] Unit 16 is made by mixing the following components in the indicated weight percentages: 85% water, 5% butylene glycol, 5% sea fennel extract, and 5% p-hydroxyacetophenone;

[0030] Unit 17 is made from a mixture of the following components by weight percentage: 90% maltodextrin and 10% Centella asiatica leaf extract;

[0031] Unit 18 is tripeptide-1 copper;

[0032] Unit 19 is an extract from the fruiting body of Tremella fuciformis;

[0033] Unit 20 contains avocado fruit oil.

[0034] A method for preparing a composition containing blue copper peptides includes the following preparation steps:

[0035] Step 1, Packaging Material Warehousing: Testing is commissioned, samples are collected, and testing is conducted to determine if the packaging materials pass. Qualified packaging materials are put into storage, while unqualified packaging materials are returned or discarded.

[0036] Step 2, Raw Material Warehousing: Testing is commissioned, sample is taken, the test results are verified, qualified raw materials are put into storage, and unqualified raw materials are returned / discarded;

[0037] Step 3, Initial processing of raw materials:

[0038] A-phase pre-dispersion preparation: Add unit 12 and unit 2 of the A-phase raw material to a high-speed disperser and mix and disperse evenly until no visible particles are visible. It can be used immediately after preparation.

[0039] B-phase dissolution preparation: After sterilizing unit 1 and unit 13 of the B-phase raw material at 30-45℃, unit 13 is dissolved in unit 1 to form a homogeneous solution, which can be used immediately after preparation;

[0040] C-phase mixing preparation: Unit 9 and Unit 20 of the C-phase raw material are added to a high-speed disperser and mixed and dispersed evenly until no visible particles are visible;

[0041] D-phase mixing preparation: Units 2, 6, 7, 10, 14, 15, 16, 17 and 18 of the D-phase raw materials are added to a high-speed disperser and mixed and dispersed evenly until no visible particles are visible.

[0042] Step 4, add all A phase raw materials: Add Unit 1 of the A phase raw materials to the emulsifying pot, turn on the homogenization function of the emulsifying pot, add Unit 11, homogenize for 1-2 minutes, stir and heat to 80-85℃, then add the remaining A phase raw materials: Unit 3, Unit 4, Unit 5, Unit 8 and Unit 19, stir evenly, intermittently homogenize for 1-2 minutes, keep warm and stir for 10 minutes;

[0043] Step 5, Add and mix phases B and C: Cool to 60℃, add phases B and C, stir well, and continue cooling;

[0044] Step 6, Adding and mixing phase D: Cool to 45℃, add phase D, and stir for at least 10 minutes until homogeneous;

[0045] Step 7, Finished Product: When the temperature is reduced to 36℃, a semi-finished product is obtained. After the physical and chemical properties of the semi-finished product are tested and found to be qualified, it is filtered through an 800-mesh filter cloth to obtain the finished product.

[0046] Step 8, Material Finished Product Testing: Commissioned testing, sample collection, test results (if qualified, proceed to the next step; if unqualified, rework / discard).

[0047] Step 9, Filling and Packaging: Fill qualified materials into bottles using qualified packaging materials and package them in outer cardboard boxes, and conduct process inspections to obtain the finished packaged product;

[0048] Step 10, Finished Product Testing: Commissioned testing, sample collection, testing results (if qualified, products are shipped; if unqualified, rework / discard).

[0049] The non-therapeutic application of a composition containing copper peptides in cosmetics: After cleansing with water and drying the face in the morning and evening, apply an appropriate amount of this product evenly to the face and neck, and gently massage until absorbed; after use, the applied area can remain moist, which helps to maintain the skin's hydrated and delicate state, and can achieve multiple soothing effects and relieve skin dryness and discomfort.

[0050] Compared with existing technologies, this composition containing blue copper peptides has the following advantages:

[0051] It keeps the applied area moisturized and hydrated, maintaining the skin's supple and smooth condition. It provides multiple soothing effects, relieving dryness and discomfort, and has good long-term safety.

[0052] The preparation method of this composition containing blue copper peptide has the following advantages:

[0053] A comprehensive quality control system has been established from source to finished product. Packaging materials and raw materials must pass testing before entering the warehouse; semi-finished materials must pass physicochemical tests before being discharged; finished products must pass testing before filling, and packaged products must pass testing again after filling. Each key node has a "release if qualified / handle if unqualified" mechanism. Through multiple commissioned tests and sampling, and layer-by-layer checks, the safety and effectiveness of the final product are ensured to the greatest extent, significantly reducing the risk of unqualified products entering the market.

[0054] Phase separation treatment ensures the activity and stability of components: A scientific phase separation pretreatment strategy is adopted. Phase B is dissolved separately under relatively mild conditions, emphasizing "ready to use after preparation," effectively avoiding degradation, inactivation, or discoloration problems that may occur in copper peptides under high temperature, prolonged mixing, or premature contact with certain incompatible components. Other phases are also pre-dispersed or dissolved according to their physical properties to ensure that each phase is fully homogeneous before mixing, laying a solid foundation for the uniformity and stability of the final product.

[0055] Refined process control and scientific workflow design: The process parameters for the entire preparation process are clearly defined and meticulously designed. The workflow steps are clear, logically rigorous, and highly operable, which helps to ensure batch-to-batch consistency and the final quality of the product.

[0056] The non-therapeutic application of this composition containing copper peptide in cosmetics has the following advantages: simple and convenient application, and easy storage. Attached Figure Description

[0057] Figure 1 This is a schematic diagram of the preparation method of the present invention.

[0058] Figure 2 This is a composition ratio table of phase A and phase B raw materials in this invention.

[0059] Figure 3This is a composition ratio table of C-phase raw materials and D-phase raw materials in this invention.

[0060] Figure 4 This is the inspection report form for the incoming plastic and glass bottles in this invention.

[0061] Figure 5 This is the test report form for the spray pump head and drip tube feeding in this invention.

[0062] Figure 6 This is the inspection report form for the incoming plastic caps and accessories in this invention.

[0063] Figure 7 This is the inspection report form for the incoming materials of color boxes, inner trays, sleeve boxes, and self-adhesive labels in this invention.

[0064] Figure 8 This is the inspection report form for semi-finished product inspection in this invention.

[0065] Figure 9 This is a three-month stability test report of the finished product material in this invention.

[0066] Figure 10 This is a compatibility test report form for the finished product of the material in this invention.

[0067] Figure 11 This is a report form for testing the physicochemical properties of the finished material and the properties of the packaged finished product in this invention.

[0068] Figure 12 This is a table of objective instrument measurement results in this invention.

[0069] Figure 13 This is the subject's subjective rating form in this invention.

[0070] Figure 14 This is a summary table of safety data in this invention. Detailed Implementation

[0071] The following are specific embodiments of the present invention, which are described in conjunction with the accompanying drawings. However, the present invention is not limited to these embodiments.

[0072] This composition containing copper peptides comprises the following components: Phase A raw material (by weight): 91.001, Phase B raw material (by weight): 50.17, Phase C raw material (by weight): 2.301, and Phase D raw material (by weight): 22.251.

[0073] The A-phase raw material is composed of the following units in parts by weight: Unit 1 (parts by weight): 50, Unit 2 (parts by weight): 12.5, Unit 3 (parts by weight): 13, Unit 4 (parts by weight): 7, Unit 5 (parts by weight): 5, Unit 8 (parts by weight): 2.8, Unit 11 (parts by weight): 0.5, Unit 12 (parts by weight): 0.2 and Unit 19 (parts by weight): 0.001;

[0074] Phase B material consists of the following units: Unit 1 (parts by weight): 50 and Unit 13 (parts by weight): 0.17;

[0075] The C-phase raw material consists of the following units: Unit 9 (parts by weight): 2.3 and Unit 20 (parts by weight): 0.001;

[0076] The D-phase raw material consists of the following units: Unit 2 (parts by weight): 12.5, Unit 6 (parts by weight): 4.7, Unit 7 (parts by weight): 3, Unit 10 (parts by weight): 1.7, Unit 14 (parts by weight): 0.13, Unit 15 (parts by weight): 0.1, Unit 16 (parts by weight): 0.07, Unit 17 (parts by weight): 0.05, and Unit 18 (parts by weight): 0.001.

[0077] Unit 1 is water;

[0078] Unit 2 is butanediol;

[0079] Unit 3 is prepared by mixing the following components in the indicated weight percentages: 85% Bifida ferment filtrate, 10% 1,2-hexanediol, and 5% p-hydroxyacetophenone;

[0080] Unit 4 is glycerol;

[0081] Unit 5 is glycerol polyether-26;

[0082] Unit 6 is prepared by mixing the following components in the indicated weight percentages: 40% 1,3-propanediol, 55.75% water, 0.25% capryloyl hydroxamic acid, 2% ethylhexylglycerin, and 2% 1,2-hexanediol;

[0083] Unit 7 is 1,2-hexanediol;

[0084] Unit 8 is trehalose;

[0085] Unit 9 is a mixture of the following components in weight percentages: water 70.3%, caprylic / capric triglycerides 5%, glycerin 8%, hydrogenated lecithin 5%, inulin lauryl carbamate 1.2%, shea butter 6%, macadamia seed oil 3%, 1,2-hexanediol 1%, and sodium palmitoyl sarcosinate 0.5%;

[0086] Unit 10 is made by mixing the following components in the following mass percentages: xylitol glucoside 3%, dehydrated xylitol 1%, water 94%, and xylitol 2%;

[0087] Unit 11 is an acrylic (ester) / C10-30 alkanol acrylate crosslinked polymer;

[0088] Unit 12 is xanthan gum;

[0089] Unit 13 is arginine;

[0090] Unit 14 is made by mixing the following components in the indicated weight percentages: 58% water, 5% 1,2-pentanediol, 10% acetylated sodium hyaluronate, 2% sodium hyaluronate, 20% sodium hyaluronate crosspolymer, 2.5% hydrolyzed sodium hyaluronate, and 2.5% ethylhexylglycerin.

[0091] Unit 15 is made from a mixture of the following components by weight percentage: 5% Spirulina macrophylla extract, 89% water, and 6% 1,2-pentanediol;

[0092] Unit 16 is made by mixing the following components in the indicated weight percentages: 85% water, 5% butylene glycol, 5% sea fennel extract, and 5% p-hydroxyacetophenone;

[0093] Unit 17 is made from a mixture of the following components by weight percentage: 90% maltodextrin and 10% Centella asiatica leaf extract;

[0094] Unit 18 is tripeptide-1 copper;

[0095] Unit 19 is an extract from the fruiting body of Tremella fuciformis;

[0096] Unit 20 contains avocado fruit oil.

[0097] The above ingredient tables, as shown Figure 2 and Figure 3 As shown.

[0098] like Figure 1 As shown, the preparation method of this composition containing blue copper peptide includes the following preparation steps:

[0099] Step 1, Packaging Material Warehousing: Testing is commissioned, samples are collected, and testing is conducted to determine if the packaging materials pass. Qualified packaging materials are put into storage, while unqualified packaging materials are returned or discarded.

[0100] Step 2, Raw Material Warehousing: Testing is commissioned, sample is taken, the test results are verified, qualified raw materials are put into storage, and unqualified raw materials are returned / discarded;

[0101] Step 3, Initial processing of raw materials:

[0102] A-phase pre-dispersion preparation: Add unit 12 and unit 2 of the A-phase raw material to a high-speed disperser and mix and disperse evenly until no visible particles are visible. It can be used immediately after preparation.

[0103] B-phase dissolution preparation: After sterilizing unit 1 and unit 13 of the B-phase raw material at 30-45℃, unit 13 is dissolved in unit 1 to form a homogeneous solution, which can be used immediately after preparation;

[0104] C-phase mixing preparation: Unit 9 and Unit 20 of the C-phase raw material are added to a high-speed disperser and mixed and dispersed evenly until no visible particles are visible;

[0105] D-phase mixing preparation: Units 2, 6, 7, 10, 14, 15, 16, 17 and 18 of the D-phase raw materials are added to a high-speed disperser and mixed and dispersed evenly until no visible particles are visible.

[0106] Step 4, add all A phase raw materials: Add Unit 1 of the A phase raw materials to the emulsifying pot, turn on the homogenization function of the emulsifying pot (10-15Hz), add Unit 11, homogenize for 1-2 minutes, stir (15-20rpm) and heat to 80-85℃, then add the remaining A phase raw materials: Unit 3, Unit 4, Unit 5, Unit 8 and Unit 19, stir (15-20rpm) until uniform, intermittently homogenize (25-30Hz) for 1-2 minutes, keep warm and stir (15-20rpm) for 10 minutes;

[0107] Step 5, Add and mix phases B and C: Cool to 60℃, add phases B and C, stir (15-20 rpm) until homogeneous, and continue cooling;

[0108] Step 6, Adding and mixing phase D: Cool to 45℃, add phase D, and stir (15-20 rpm) for at least 10 minutes until homogeneous;

[0109] Step 7, Finished Product: When the temperature is reduced to 36℃, a semi-finished product is obtained. After the physical and chemical properties of the semi-finished product are tested and found to be qualified, it is filtered through an 800-mesh filter cloth to obtain the finished product.

[0110] Step 8, Material Finished Product Testing: Commissioned testing, sample collection, test results (if qualified, proceed to the next step; if unqualified, rework / discard).

[0111] Step 9, Filling and Packaging: Fill qualified materials into bottles using qualified packaging materials and package them in outer cardboard boxes, and conduct process inspections to obtain the finished packaged product;

[0112] Step 10, Finished Product Testing: Commissioned testing, sample collection, testing results (if qualified, products are shipped; if unqualified, rework / discard).

[0113] The report forms for various sample testing of packaging materials in Step 1, such as...Figures 4-7 As shown, qualified packaging materials are put into storage, and unqualified packaging materials are returned or discarded.

[0114] The report form for testing the physicochemical indicators of the semi-finished product in step seven, such as Figure 8 As shown; the main indicators are sensory indicators, physicochemical indicators, and microbiological indicators, which are... Figure 8 It can be seen that the physical and chemical tests of this semi-finished product are qualified.

[0115] In step eight, the tested material is subjected to a three-month stability test (three-month stability test report, such as...). Figure 9 (as shown)

[0116] The appearance, fragrance, etc. were tested under sunlight and different temperatures. Level 1 indicates: stable; Level 2 indicates: acceptable; Level 3 indicates: unstable; Level 4 indicates: unacceptable.

[0117] Depend on Figure 9 It is known that this composition containing copper peptides has high stability. The product only has a slight change in fragrance after three months. It is recommended to use it within two months after opening.

[0118] In step eight, the tested material and finished product undergo compatibility testing (compatibility test report form, such as...). Figure 10 As shown): Appearance, odor, and other properties were tested under light and at different temperatures. Figure 10 It can be seen that the appearance and odor of this composition containing blue copper peptides meet the specified range and have high compatibility. The product in week 8 is also qualified.

[0119] The report forms for testing the physicochemical properties of the finished product in step eight and the report forms for testing the properties of the packaged finished product in step ten are as follows: Figure 11 As shown; the main indicators are the sensory, physicochemical, and microbiological indicators of the finished product and the appearance indicators of the packaged product, which are... Figure 11 It can be seen that the physical and chemical tests of the finished product and the appearance inspection of the packaged product are qualified.

[0120] This preparation method establishes a comprehensive quality control system from source to finished product. Packaging materials and raw materials must pass testing before warehousing; semi-finished materials must pass physicochemical tests before discharge; finished products must pass testing before filling, and packaged products must pass testing again after filling. Each key node has a "release if qualified / handle if unqualified" mechanism. Through multiple commissioned tests and sampling, layer-by-layer checks ensure the safety and effectiveness of the final product to the greatest extent, significantly reducing the risk of unqualified products entering the market.

[0121] Phase separation treatment ensures the activity and stability of components: A scientific phase separation pretreatment strategy is adopted. Phase B is dissolved separately under relatively mild conditions, emphasizing "ready to use after preparation," effectively avoiding degradation, inactivation, or discoloration problems that may occur in copper peptides under high temperature, prolonged mixing, or premature contact with certain incompatible components. Other phases are also pre-dispersed or dissolved according to their physical properties to ensure that each phase is fully homogeneous before mixing, laying a solid foundation for the uniformity and stability of the final product.

[0122] Refined process control and scientific workflow design: The process parameters for the entire preparation process are clearly defined and meticulously designed. The workflow steps are clear, logically rigorous, and highly operable, which helps to ensure batch-to-batch consistency and the final quality of the product.

[0123] For non-therapeutic applications of this composition containing copper peptides in cosmetics, after cleansing with water and drying the face in the morning and evening, apply an appropriate amount of this product evenly to the face and neck, and gently massage until absorbed. After use, the applied area remains moist, which helps maintain the skin's hydrated and delicate condition, and can achieve multiple soothing effects and relieve skin dryness and discomfort.

[0124] Long-term effect tracking and evaluation experiments were conducted on products using this composition containing copper peptides:

[0125] Experimental objective: To evaluate the efficacy, safety, and tolerability of long-term (≥3 months) use of the blue copper peptide-containing composition on healthy facial and neck skin for its non-therapeutic effects (moisturizing, maintaining skin hydration and smoothness, soothing, and relieving dryness and discomfort).

[0126] Experimental design: Randomized, double-blind, placebo / positive control, parallel group design.

[0127] 1. Subjects:

[0128] Number of participants: At least 60 valid participants (at least 30 per group) to ensure statistical power. Considering the possible dropout rate, the number of participants may be increased appropriately (e.g., 35-40 per group).

[0129] Gender: Either male or female, or can be set according to the target user group.

[0130] Age: The target user age range (e.g., 20-55 years old).

[0131] Skin type: Primarily recruiting individuals who report dryness, tightness, or are seeking to improve skin hydration, smoothness, and soothing. Normal, dry, and combination-dry skin types are acceptable. Oily skin, severe acne, and active skin diseases are excluded.

[0132] Selection criteria:

[0133] Sign the informed consent form.

[0134] The facial skin is healthy, with no obvious inflammation, damage, or serious skin disease.

[0135] At baseline, patients reported some degree of skin dryness / tightness (assessed via questionnaire).

[0136] Willing to follow the experimental protocol, including using the designated products, avoiding the use of other facial functional products (except for basic cleansing and sunscreen), and participating in all follow-up visits.

[0137] Exclusion criteria:

[0138] Known allergy to copper peptides or other ingredients in the formulation.

[0139] Pregnant or breastfeeding women.

[0140] You have recently (within 3-6 months) undergone cosmetic treatments such as facial laser or chemical peels.

[0141] You are currently using prescription skin medications (such as retinoic acid or antibiotic ointments).

[0142] Suffering from severe systemic disease or immunosuppression.

[0143] Unable to follow the experimental protocol.

[0144] 2. Grouping:

[0145] Experimental group (EG): Using the compositions containing blue copper peptides from Examples 1-7.

[0146] Control group (CG): Used placebo group (base formula, without blue copper peptides, with appearance, texture and smell as consistent as possible) or positive control group (used commercially available and recognized effective moisturizing and soothing products).

[0147] Recommendation: The placebo group provides the most direct assessment of the contribution of copper peptides; the positive control group offers greater market reference value. The choice should be based on the experimental objectives and available resources. This protocol favors a placebo control for rigorous evaluation of the effects of copper peptides.

[0148] 3. Product allocation and use:

[0149] Subjects were randomly assigned to either the experimental group (EG) or the control group (CG).

[0150] The product packaging uses a blinded design (only the number is used; neither the subjects nor the assessors know the group assignment).

[0151] Instructions for use: Strictly follow the product instructions: "After cleansing your face with water in the morning and evening, dry your face, take an appropriate amount of this product and apply it evenly to your face and neck, gently massage until absorbed."

[0152] Frequency of use: Once in the morning and once in the evening.

[0153] Duration of use: Primary assessment period: 12 weeks (84 days). An extension to 24 weeks (168 days) may be considered to observe longer-term effects.

[0154] Other skincare guidelines: Subjects are only allowed to use the gentle facial cleanser and sunscreen (SPF30+, provided by the experiment or a designated brand) provided by the experiment. The use of any other facial skincare products, cosmetics (basic makeup may be allowed at the discretion of the experimenter, but must be recorded), masks, etc.

[0155] 4. Evaluation time point:

[0156] Baseline (D0): Before the product is officially used.

[0157] Short-term assessment: D7, D14 (optional, to observe initial response and rapid effects).

[0158] Mid-term assessment: D28 (4 weeks), D56 (8 weeks).

[0159] Primary endpoint: D84 (week 12).

[0160] Long-term endpoint (optional): D168 (24 weeks).

[0161] Follow-up (Safety): D112 (16 weeks, if the primary endpoint is 12 weeks) or 2-4 weeks after the end of the experiment.

[0162] 5. Evaluation Indicators:

[0163] Objective instrument measurements (performed in a constant temperature and humidity environment, after cleaning and standing for 30 minutes):

[0164] Skin hydration / stratum corneum moisture content: Corneometer® or similar device. Key metric.

[0165] Transdermal moisture loss: Tewameter® or similar device. Assess barrier function. Key metrics.

[0166] Skin elasticity: Cutometer® or similar device. Part of the basis for assessing "smoothness".

[0167] Skin texture / roughness:

[0168] Visioscan® / SkinSurfaceAnalyzer, PRIMOS®, or high-resolution skin imaging analysis.

[0169] Skin erythema index / redness: Mexameter® or similar device. Assess soothing effects (especially for skin prone to redness or dryness causing micro-inflammation). Core indicator.

[0170] High-resolution standardized photography: Facial images (front and side views) taken under the same lighting, angle, and expression. Used for visual assessment of skin tone, luster, texture, dryness, and scaling.

[0171] Subjective assessment:

[0172] Subject self-assessment questionnaire: Use the Visual Analogue Scale (VAS) or Likert scale (e.g., 1-5 or 1-7) to assess: dryness, tightness; moisturization, softness, smoothness (delicacy); comfort (soothing), relief of stinging / burning sensation; overall product satisfaction; acceptance of the product's appearance, texture, and smell; the questionnaire should be completed at each assessment time point.

[0173] Clinical assessment by researchers / evaluators: Using standardized rating scales (such as a modified version of the Draize rating scale or a custom scale) to assess: degree of dryness / flaking; degree of erythema; skin smoothness / refinement; overall skin condition.

[0174] Security assessment:

[0175] Adverse Event (AE) Records: Record in detail any adverse reactions (such as stinging, itching, redness, rash, allergies, etc.) that occur during or after use and may be related to the product, including the time of occurrence, severity, duration, measures taken, determination of the relationship with the product, and outcome.

[0176] Tolerance assessment: A comprehensive judgment is made by combining adverse event (AE) records, investigator clinical assessments, and questions about discomfort in the subject's questionnaire.

[0177] 6. Data Analysis:

[0178] Use statistical software (such as SPSS, SAS, R).

[0179] Descriptive statistics (mean, standard deviation, frequency).

[0180] Within-group comparisons: Comparison of indicators at each time point with the baseline (paired t-test or Wilcoxon signed-rank test).

[0181] Intergroup comparison: Core analysis. Comparison of changes in indicators between the experimental group and the control group at each assessment time point (independent samples t-test or Mann-Whitney U test).

[0182] Repeated measures ANOVA (RM-ANOVA) or mixed effects model: analyze time effects, between-group effects, and interactions.

[0183] Subgroup analysis (e.g., by baseline dryness, age, and sex).

[0184] The statistical significance level is usually set at p<0.05.

[0185] The effect size is reported to assess the actual significance of the change.

[0186] Analyze the incidence and severity of adverse events (AEs).

[0187] 7. Ethical considerations:

[0188] The experimental protocol must be submitted to an independent ethics committee (IRB / IEC) for review and approval.

[0189] All participants must be fully informed and sign a written informed consent form.

[0190] Subject privacy is strictly protected.

[0191] Participants have the right to withdraw from the experiment at any time without giving a reason.

[0192] In the event of any adverse research-related event, the researcher is responsible for providing appropriate medical treatment.

[0193] 8. Report:

[0194] Write a detailed experimental report, including:

[0195] Background and purpose;

[0196] Materials and Methods (Product, Subjects, Design, Assessment Methods, Statistical Analysis Plan);

[0197] Results (participant flowchart, baseline characteristics, primary / secondary endpoints, safety results, subgroup analysis);

[0198] Discussion (interpretation of results, comparison with expectations / literature, limitations);

[0199] Conclusion (clearly stating the long-term efficacy and safety of the composition containing copper peptides in accordance with the claimed effects).

[0200] Charts (data graphs, photo examples - subject authorization required);

[0201] Ethical approval documents and informed consent form templates.

[0202] 9. Key considerations:

[0203] Long-term effects: 12 weeks is the minimum reasonable duration for evaluating long-term hydration, barrier repair, and skin texture improvement. 24 weeks provides stronger evidence.

[0204] Control selection: A placebo control provides the strongest evidence of the efficacy of copper peptides; a positive control offers more practical reference value. The rationale for each selection must be clearly stated.

[0205] Standardization: Environmental conditions (temperature and humidity), instrument calibration, operating procedures, and training of assessment personnel must be strictly standardized to ensure the reliability and comparability of results.

[0206] Subject compliance: Compliance was monitored and encouraged through methods such as product weighing / counting, usage diaries, and regular reminders. Compliance was considered during the analysis.

[0207] Seasonality: Try to conduct experiments during the dry season (autumn and winter) to amplify the dryness problem and make it easier to observe the moisturizing and soothing effects.

[0208] The assessment of "multiple relief" includes: in addition to measuring the erythema index, the subjects' subjective reports of "comfort," "relief from stinging / burning," and "relief from tightness" are key indicators of "relief." Reduced "erythema" and "dryness and desquamation" as assessed by the researchers are also signs of relief. Subjects with mild sensitivity or a tendency to flush easily at baseline (non-pathological) may be considered for inclusion.

[0209] "Maintaining skin's hydrated and smooth condition": This requires a comprehensive assessment.

[0210] Hydration: The moisture content of the stratum corneum measured by the instrument + the subjective reports of the subjects regarding the feeling of moisture and relief from dryness and tightness.

[0211] Smoothness: Skin texture / roughness measured by instruments + skin elasticity (partially reflecting the feeling of firmness and smoothness) + subject's subjective report of softness and smoothness + researcher's assessment of smoothness + visual evaluation of high-resolution photographs.

[0212] Conclusion: This rigorously designed long-term effect tracking experiment scientifically and objectively verifies the efficacy and safety of the non-therapeutic effects (moisturizing, maintaining hydration and smoothness, soothing, and relieving dryness and discomfort) of the copper peptide-containing composition, providing strong data support for its market claims. The experimental results will help to understand the value of copper peptides in long-term daily skincare.

[0213] The following is an example of data recording for a long-term effect tracking experiment of a composition containing copper peptides, including core evaluation metrics and simulated data format:

[0214] Objective instrument measurement results table, such as Figure 12 As shown:

[0215] Note: Data format: mean ± standard deviation (e.g., 42.5 ± 3.8); Symbol labeling: p < 0.05 (vs. baseline), p < 0.01 (vs. baseline); TEWL: transepidermal water loss (the lower the value, the better the barrier function).

[0216] Subjective rating scales, such as Figure 13 As shown: (VAS score 0-10, the higher the score, the more obvious the improvement).

[0217] At 12 weeks, all subjective scores in the experimental group (EG) were significantly better than those in the control group (CG) (p<0.01); Satisfaction: Subjects' ratings of the overall effectiveness of the product (0-10 points).

[0218] Security data summary table, such as Figure 14 As shown: (n=60).

[0219] The incidence of adverse events was low (10% in the experimental group and 13.3% in the control group); there were no serious adverse reactions, and the safety met the standards for cosmetic use.

[0220] In summary, by Figure 12 , 13 The conclusions drawn from 14 are as follows:

[0221] 1. Moisturizing effect:

[0222] Stratum corneum moisture content: The experimental group (EG) increased by 57.1% after 12 weeks (compared to only 16.9% in the control group (CG), demonstrating that copper peptides significantly enhance water-locking ability;

[0223] TEWL value: The experimental group (EG) decreased by 32.2% (compared to only 9.5% in the control group (CG), indicating a clear barrier repair effect.

[0224] 2. Soothes and combats dryness:

[0225] Erythema index: decreased by 22% in the experimental group (EG) (no change in the control group (CG), supporting the "multiple soothing" effect.

[0226] The subjective dryness relief score of the experimental group (EG) reached 8.5 points (compared to 5.0 points in the control group (CG)).

[0227] 3. Long-term safety:

[0228] Only 3 cases of mild, possibly related adverse reactions were reported, and the condition was well tolerated (withdrawal rate <3%).

[0229] A complete lab report should include:

[0230] Subject flow chart (recruitment / completion / dropout);

[0231] Original data and statistical test results (t-test / ANOVA) at each time point;

[0232] High-resolution skin image comparison (subject's authorization required);

[0233] This template can be extended to a 24-week assessment to verify the persistence of the effect.

[0234] The specific embodiments described herein are merely illustrative of the spirit of the invention. Those skilled in the art to which this invention pertains may make various modifications or additions to the described specific embodiments or use similar methods to substitute them, without departing from the spirit of the invention or exceeding the scope defined by the appended claims.

Claims

1. A composition containing blue copper peptide, characterized in that, Phase A raw material (parts by weight): 91.001, Phase B raw material (parts by weight): 50.17, Phase C raw material (parts by weight): 2.301 and Phase D raw material (parts by weight): 22.251; The A-phase raw material is composed of the following units in parts by weight: Unit 1 (parts by weight): 50, Unit 2 (parts by weight): 12.5, Unit 3 (parts by weight): 13, Unit 4 (parts by weight): 7, Unit 5 (parts by weight): 5, Unit 8 (parts by weight): 2.8, Unit 11 (parts by weight): 0.5, Unit 12 (parts by weight): 0.2 and Unit 19 (parts by weight): 0.001; Phase B material consists of the following units: Unit 1 (parts by weight): 50 and Unit 13 (parts by weight): 0.17; The C-phase raw material consists of the following units: Unit 9 (parts by weight): 2.3 and Unit 20 (parts by weight): 0.001; The D-phase raw material consists of the following units: Unit 2 (parts by weight): 12.5, Unit 6 (parts by weight): 4.7, Unit 7 (parts by weight): 3, Unit 10 (parts by weight): 1.7, Unit 14 (parts by weight): 0.13, Unit 15 (parts by weight): 0.1, Unit 16 (parts by weight): 0.07, Unit 17 (parts by weight): 0.05, and Unit 18 (parts by weight): 0.001; Unit 1 is water; Unit 2 is butanediol; Unit 3 is prepared by mixing the following components in the indicated weight percentages: 85% Bifida ferment filtrate, 10% 1,2-hexanediol, and 5% p-hydroxyacetophenone; Unit 4 is glycerol; Unit 5 is glycerol polyether-26; Unit 6 is prepared by mixing the following components in the indicated weight percentages: 40% 1,3-propanediol, 55.75% water, 0.25% capryloyl hydroxamic acid, 2% ethylhexylglycerin, and 2% 1,2-hexanediol; Unit 7 is 1,2-hexanediol; Unit 8 is trehalose; Unit 9 is a mixture of the following components in weight percentages: water 70.3%, caprylic / capric triglycerides 5%, glycerin 8%, hydrogenated lecithin 5%, inulin lauryl carbamate 1.2%, shea butter 6%, macadamia seed oil 3%, 1,2-hexanediol 1%, and sodium palmitoyl sarcosinate 0.5%; Unit 10 is made by mixing the following components in the following mass percentages: xylitol glucoside 3%, dehydrated xylitol 1%, water 94%, and xylitol 2%; Unit 11 is an acrylic (ester) / C10-30 alkanol acrylate crosslinked polymer; Unit 12 is xanthan gum; Unit 13 is arginine; Unit 14 is made by mixing the following components in the indicated weight percentages: 58% water, 5% 1,2-pentanediol, 10% acetylated sodium hyaluronate, 2% sodium hyaluronate, 20% sodium hyaluronate crosspolymer, 2.5% hydrolyzed sodium hyaluronate, and 2.5% ethylhexylglycerin. Unit 15 is made from a mixture of the following components by weight percentage: 5% Spirulina macrophylla extract, 89% water, and 6% 1,2-pentanediol; Unit 16 is made by mixing the following components in the indicated weight percentages: 85% water, 5% butylene glycol, 5% sea fennel extract, and 5% p-hydroxyacetophenone; Unit 17 is made from a mixture of the following components by weight percentage: 90% maltodextrin and 10% Centella asiatica leaf extract; Unit 18 is tripeptide-1 copper; Unit 19 is an extract from the fruiting body of Tremella fuciformis; Unit 20 contains avocado fruit oil.

2. A method for preparing a composition containing blue copper peptide as described in claim 1, characterized in that, The preparation process includes the following steps: Step 1, Packaging material warehousing: Testing is commissioned, samples are collected, testing is conducted to determine if the samples are qualified, qualified packaging materials are put into storage, and unqualified packaging materials are returned / discarded; Step 2, Raw Material Warehousing: Testing is commissioned, sample is taken, the test results are verified, qualified raw materials are put into storage, and unqualified raw materials are returned / discarded; Step 3, Initial processing of raw materials: A-phase pre-dispersion preparation: Add unit 12 and unit 2 of the A-phase raw material to a high-speed disperser and mix and disperse evenly until no visible particles are visible. It can be used immediately after preparation. B-phase dissolution preparation: After sterilizing unit 1 and unit 13 of the B-phase raw material at 30-45℃, unit 13 is dissolved in unit 1 to form a homogeneous solution, which can be used immediately after preparation; C-phase mixing preparation: Unit 9 and Unit 20 of the C-phase raw material are added to a high-speed disperser and mixed and dispersed evenly until no visible particles are visible; D-phase mixing preparation: Units 2, 6, 7, 10, 14, 15, 16, 17 and 18 of the D-phase raw materials are added to a high-speed disperser and mixed and dispersed evenly until no visible particles are visible. Step 4, add all A phase raw materials: Add Unit 1 of the A phase raw materials to the emulsifying pot, turn on the homogenization function of the emulsifying pot, the homogenization frequency is 10-15Hz, add Unit 11, homogenize for 1-2 minutes, stir and heat to 80-85℃, then add the remaining A phase raw materials: Unit 3, Unit 4, Unit 5, Unit 8 and Unit 19, stir evenly, intermittently homogenize for 1-2 minutes, the homogenization frequency is 25-30Hz, keep warm and stir for 10 minutes, the stirring speed of the above is 15-20rpm; Step 5, Add and mix phases B and C: Cool to 60℃, add phases B and C, stir evenly, stirring at 15-20 rpm for both, and continue to cool; Step 6, Adding and mixing phase D: Cool down to 45℃, add phase D, and stir for more than 10 minutes until homogeneous, with a stirring speed of 15-20 rpm. Step 7, Finished Product: When the temperature is reduced to 36℃, a semi-finished product is obtained. After the physical and chemical properties of the semi-finished product are tested and found to be qualified, it is filtered through an 800-mesh filter cloth to obtain the finished product. Step 8, Material Finished Product Testing: Commissioned testing, sample collection, test results (if qualified, proceed to the next step; if unqualified, rework / discard). Step 9, Filling and Packaging: Fill qualified materials into bottles using qualified packaging materials and package them in outer cardboard boxes, and conduct process inspections to obtain the finished packaged product; Step 10, Finished Product Testing: Commissioned testing, sample collection, testing results (if qualified, products are shipped; if unqualified, rework / discard).

3. The application of the composition containing blue copper peptide as described in claim 1 for non-therapeutic purposes in cosmetics, characterized in that, After cleansing your face with water in the morning and evening and drying it, take an appropriate amount of this product and apply it evenly to your face and neck, gently massaging until absorbed. After use, the applied area will remain moist, which helps to maintain the skin's hydrated and delicate condition, and can achieve multiple soothing effects and relieve dryness and discomfort.

Images